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ABSTRACT 
 
Ex-Vivo Model for Muscle Exposure to Tumor Cell Conditioned 
Media 
 
Ikttesh K. Chahal 
 
Cancer-induced cachexia is a severe condition resulting in muscle wasting, muscle dysfunction, 
and an overall increased morbidity and mortality. The cachectic condition is often attributed to 
altered metabolism, aberrant activation of signaling pathways, and changes in the 
microenvironment of the skeletal muscle (SKM) through exposure to various host-derived and 
tumor-derived paracrine factors, delivered through the blood circulation. Previous data from our 
lab has shown that an increased signaling of Interleukin-15 (IL-15) results in enhanced oxidative 
capacity, promotion of a more oxidative phenotype and attenuation of muscle fatigue. This effect 
of IL-15 has yet to be characterized in a cancer-induced model of muscle dysfunction. Therefore, 
through this project, we sought to establish an ex-vivo working model for muscle exposure to 
tumor cell conditioned media using an IL-15TG overexpressing IL-15 mouse model; thereby 
allowing to test IL-15’s role in the JAK/STAT signaling pathway, an oncogenic signaling 
cascade that exerts tumor-intrinsic and tumor-extrinsic effects. Current studies investigating the 
role of tumor secreted factors on muscle function in-vitro do so by exposing muscle cells to 
solutions containing tumor cell conditioned media. However, this is an incomplete representation 
and assessment of the in-vivo system.  In our improved model, the whole extensor digitorum 
longus (EDL) muscles are used in combination with human breast cancer cell line conditioned 
media (CM). We hypothesized that the cancer cell-secreted factors will induce muscle 
dysfunction and affect mediators of the JAK/STAT pathway in comparison to control 
unconditioned media (UCM). Our initial analyses using the EDL muscles from WT mice, IL-
15TG littermate control mice, and IL-15TG overexpressing IL-15 mice revealed no significant 
differences in the functional output in either CM or UCM conditions. However, recent literature 
suggests that at least a 2 hour pre-incubation period is needed to see analogous effects seen with 
a shared circulation of cancer cell-secreted factors and muscle cells in-vivo. Additional 
experiments using an extended exposure are needed to improve the translational potential of the 
proposed model. However, our western blot analyses revealed a statistical significance (p<0.05) 
in the phosphorylated STAT3 (pSTAT3) in the stimulated CM compared to the stimulated UCM 
conditions in the TG group. This finding is supported in the literature and suggests that samples 
that undergo stimulation and are exposed to CM show a higher phosphorylation of STAT3. It 
also validates the overexpressing properties of the IL-15TG mouse since IL-15 binding is known 
to induce and activate the JAK3/STAT3 pathway. In conclusion, this research provides support 
for further development of this ex-vivo muscle exposure to tumor cell conditioned media model.   	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CHAPTER 1. 
Introduction   
  Cancer-associated muscle weakness is a well-observed syndrome for which there is 
currently no treatment. Muscle weakness can be caused by reduced muscle mass or reduced 
muscle function and in advanced diseases, including cancer, it is likely due to a combination of 
both. Aside from a significantly decreased quality of life, the overall prognosis associated with 
cancer cachexia, which is defined as muscle wasting and muscle dysfunction, accounts for 
approximately 40-50% of cancer patient morbidity [1]. Although cachexia is considered as an 
important factor associated with cancer-related deaths, no experimental link has been determined 
to show the exact mechanism by which this syndrome arises [2]. The literature proposes that the 
main contributors of cachexia are abnormal fluctuations in cytokines, hormones and tumor-
derived factors that alter the cellular environment and thereby exacerbate cachectic symptoms 
[1]. This may be due in part to a reduction of mitochondrial function in cancer cachexia leading 
to loss of muscle function. Studying the effects of the altered biomarkers, signaling pathways, 
and their subsequent effect on gene expression is a potential avenue to further understand the 
mechanisms involved in cancer cachexia. Previous work from our lab suggests that increasing 
signaling of the cytokine Interleukin-15 (IL-15) increases mitochondrial mass, and enhances 
oxidative capacity in skeletal muscle [3, 4]. However, we do not know if the effect of IL-15 will 
improve these conditions in a cancer-induced model of muscle dysfunction.   
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  A second potential mediator of muscle atrophy seen in cancer cachexia may be via the 
Janus kinase and signal transducers and activators of transcription (JAK/STAT) signaling 
pathway as it is an important oncogenic signaling cascade that exerts tumor-intrinsic and tumor-
extrinsic effects, supporting tumor survival and metastasis [5]. Inhibition of the JAK/STAT 
pathway has been shown to reduce cancer hallmarks such as proliferation, survival, 
angiogenesis, and tumor metabolism [6]. Once activated, JAK proteins phosphorylate tyrosine 
residues present in the cytoplasmic region of the receptor, thereby creating binding sites for 
STATs [7]. These STAT proteins form dimers, allowing them to be further activated through 
phosphorylation. These phosphorylated dimers termed pSTAT translocate to the nucleus and 
bind specific promoter sequences to modulate gene transcription of cellular processes involving 
proliferation, differentiation and apoptosis [7]. Further, activation of pSTAT3 has also been 
reported to induce the activation of two different proteolytic pathways in the muscle – caspase 3, 
and the MAFbx/Atrogin-1 and MuRF-1 pathway [8]. Our preliminary data shows a potential role 
for the JAK/STAT signaling pathway downstream of IL-15 binding, impacting muscle function 
and mass in cancer cachexia. Therefore, it is expected that through this project we will be able to 
use a model that links muscle function and signaling pathways while closely mimicking 
conditions that are seen in vivo. 
  Our central aim was to evaluate JAK/STAT IL-15 regulation in cancer cachexia using an 
ex-vivo model that can emulate a system seen in tumor-bearing animals. In this model, a whole 
muscle is constantly exposed to tumor-produced factors via incubation in conditioned media 
used to culture a human breast cancer cell line – MDA-MB-231. We measured the expression 
levels and associated phosphorylation levels of certain mediators in the JAK/STAT pathway 
(such as STAT3 and pSTAT3) that directly affect gene expression. In doing so, we determined a 
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link between the functional properties of a whole muscle and mediators of the pathway 
downstream of IL-15 binding. Traditionally, the effects of conditioned media have been 
observed in individual cells such as myocytes [8, 9]. However, the effects have not been reported 
on a functional muscle since the development of an external environment with minimal alteration 
to natural conditions has not yet been achieved. Another key component of this project was that 
the contractile data was analyzed from the whole muscle, which permitted us to have a functional 
output, contributing to the novelty of this project. In this research, we used two different mouse 
models, including wild type mice (WT; strain C57BL/6J) and transgenic mice (IL-15TG – over 
expressers of IL-15). These mouse models allowed us to build on the results of the preliminary 
data and previously published work by our laboratory. We expected that the protein levels of the 
mediators downstream of IL-15 binding through the JAK/STAT pathway such as 
phosphorylation of STAT3 would be elevated in the overexpressing IL-15 mouse model in 
comparison to their littermate controls. We also expected to see similar trends with the muscle 
function of the IL-15TG mice as the pro-oxidative state and elevated fatigue resistance 
phenotype may in fact aid in decreasing symptoms associated with cancer cachexia. 
 
Specific Aim 1: Determine the effects of conditioned media used to grow cancer cells on ex-
vivo muscle function.   
  Our working hypothesis is that 25% diluted conditioned media will reduce ex vivo 
muscle function causing reduced contractile forces when compared to the muscle function using 
control media (25% diluted unconditioned media). From our preliminary data, we know that 
tumors produced by orthotopic injection of EO771 murine mammary gland cancer cell line into 
syngeneic C57BL/6J mice cause muscle dysfunction and muscle wasting. However, we do not 
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know if it is the cancer cell-derived factors that are causing this muscle fatigue and muscle 
wasting. Therefore, we want to evaluate this effect using an ex-vivo whole muscle model where 
individual components, muscles, tumor cells, or tumor cell-derived factors could be evaluated. 
We expect to see a decrease in muscle force output in the muscles exposed to 25% diluted 
conditioned media from the MDA-MB-231 human breast cancer cell line in comparison to 25% 
diluted unconditioned media. Similarly, the skeletal muscle from IL-15TG mouse is expected to 
demonstrate a greater preservation of muscle force. 
 
Specific Aim 2: Determine the effects of 25% diluted conditioned media on the mediators in 
the JAK3/STAT3 signaling pathway in an ex vivo model. 
  Our working hypothesis is that cancer cell-derived factors in conditioned media will have 
an effect on JAK3/STAT3 pathway activation. From our preliminary data, we observed 
increased mRNA expression of both, Murf-1 and Atrogin-1, markers of muscle atrophy, when 
exposed to conditioned media from EO771 cells, a cultured murine cancer cell line. However, 
effects of cancer cell-derived factors on the phosphorylation of proteins such as JAK3, STAT3, 
STAT5 had not been determined prior to our study. Western blot analyses will be used to 
measure expression level of JAK/STAT proteins and their phosphorylation in protein 
homogenates obtained from mice extensor digitorum longus (EDL) muscles exposed to 25% 
diluted conditioned media, in comparison to control protein homogenates of mice EDLs exposed 
to 25% diluted unconditioned media.  
 
 
 
 
5 
 
 
CHAPTER 2. 
Literature Review 
 
2.1 Cancer Cachexia  
  Cancer is a major public health problem worldwide, with an estimated 14.1 million new 
cases of cancer diagnoses annually [10]. In 2017, the American Cancer Society (ACS) estimated 
that in the United States, over 600,000 deaths are due to cancer yearly; making it the second 
leading cause of death [10]. Cancer-induced cachexia, a syndrome characterized by loss of 
muscle mass, fatigue and weakness is experienced by almost fifty percent of all cancer patients 
[11]. A greater prevalence is observed in patients with advanced stage cancers, with almost 
eighty percent of patients presenting with this severe wasting syndrome [1, 12]. Despite being 
considered as an emerging field of research, the molecular mechanisms leading to skeletal 
muscle loss with cachexia are still largely unknown. Currently, there are no approved drug 
therapies or effective medical interventions that completely reverse cancer cachexia [13]. 
  Cancer cachexia can be characterized by loss or extreme atrophy of skeletal muscle mass 
that may or may not be accompanied by loss of fat mass [10]. Another key component of cancer 
cachexia is severe fatigue in patients, which is commonly credited to the loss of muscle mass [2]. 
However, it has been shown that cancer-induced muscle fatigue can occur without loss of muscle 
mass [1]. Figure 1 represents the common presentations seen in cachexia that include 
inflammation, anorexia and hormonal aberrations. Changes in the microenvironment of the 
skeletal muscle through exposure to various host-derived and tumor-derived paracrine factors 
delivered through the blood circulation are now being studied and attributed as possible causes of 
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this disease [1], [14]. Specifically, evidence suggests that markers of inflammation and 
biomarkers contributing to protein degradation can contribute to cachectic symptoms [15, 16].  
 In particular, studies evaluating the metabolic alterations leading to cancer cachexia have 
revealed pathways including the NF-κB (nuclear factor kappa-light-chain-enhancer of activated 
B cells) and JAK/STAT pathway [17]. Similarly, the ubiquitin-proteasome system (UPS) 
pathway has also been shown to play a key role in muscle protein breakdown, especially through 
activation of its main regulators - ubiquitin E3 ligases, muscle ring finger protein 1 (MuRF-1), 
and atrophy gene 1/muscle atrophy F-box (Atrogin-1/MAFbx) [16–19]. Further investigation is 
needed in studying the different mediators of these signaling pathways as they can serve as 
potential therapeutic opportunities. In fact, a first-in-human outpatient phase I dose escalation 
trial of subcutaneous (SC) recombinant human IL-15 (rhIL-15) was recently conducted to study 
the effectiveness and safety of rhIL-15 in treating refractory solid tumors in cancer patients [20]. 
IL-15, being a powerful immunostimulatory cytokine, is involved in the proliferation, 
differentiation, and activation of NK cells and CD8+ T cells, and actually utilizes certain 
JAK/STAT proteins as a means of initiating signal transduction for cellular activation [21]. 
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Figure 1: Conceptual definition of cachexia through a schematic. 
Above image from Evans et al. [15] represents the conceptual definition of cachexia seen in a chronic 
disease. Inflammation, anorexia, and hormonal aberrations are common presentations.  
 
 
 
2.2 Models of Cancer Cachexia 
  Despite the lack of approved therapies or treatments for cancer cachexia, multiple models 
of cancer cachexia are being used to gain insight into the mechanisms behind muscle wasting, as 
well as potential therapeutic targets [22]. Many studies are employing the use of animal models; 
by either genetically modifying the animals or through tumor implantation, to understand these 
underlying mechanisms. Since cytokines, myokines, and other factors also contribute to muscle 
mass regulation, cell culture models are also used to study signaling pathways and their 
responses. There are many benefits to using cultured cell lines in cancer research; a major benefit 
is that cell lines self-replicate and supply a relatively homogeneous cell population using a 
standard cell culture medium [23]. One of the most widely used breast cancer cell lines is MDA-
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MB-231, a metastatic mammary carcinoma cell line that was established in 1973 at M.D Anderson 
Cancer Center [24, 25]. This human cell line is typically used as a model for estrogen receptor-
negative breast cancers and is highly aggressive both in vitro and in vivo [26, 27]. Therefore, 
MDA-MB-231 is a valuable cell culture model to study cancer cachexia due to its invasive and 
metastatic properties.  
  Currently, different groups are using such models to study different cancer types and their 
presentations. Puppa et al. [28] reported a 16% skeletal muscle attenuation in gp130-KO mice in 
comparison to wild-type mice, in which both of the groups were subjected to Lewis lung 
carcinoma (LLC) cells. Glycoprotein 130 (gp130) is a common signal transducer that typically 
activates STAT3, an intracellular transcription factor implicated in stimulating protein muscle 
loss [8, 29]. They reported decreases in LLC-induced phosphorylation of muscle STAT3 and 
FOXO3, a tumor suppressor gene [28, 30]. Through in vitro experiments using C2C12 
myotubes, they reported a repression in LLC-induced atrophy signaling [28]. However, they 
concluded that further development of this cachexia model is needed since the inhibition of skm-
gp130 was not sufficient to suppress the LLC-induced signaling of atrophic pathways [28]. 
Investigators using the mouse C26 colon carcinoma cancer model treated C2C12 myotubes with 
conditioned medium from C26 cancer cells to observe the signaling pathways activated in this 
model of induced atrophy [31]. They reported an increase in STAT activation through STAT3 
phosphorylation and myotube atrophy induced by C26 conditioned media [31]. Another group 
using the C26 model reported similar mouse myotube atrophy using conditioned media by 
measuring myotube diameter [9]. However, this response is less in vitro when compared to in 
vivo muscles of mice bearing C26 tumors [9]. Using transcriptomic and metabolomic profiling, 
Fukawa et al. [32] observed impaired muscle growth, increased oxidative stress through 
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excessive fatty acid oxidation in human myotubes, suggesting the importance of experiments 
using myotubes to study the different atrophy-inducing conditions. These studies propose 
conditions analogous to those in-vivo as they are all trying to stimulate an environment 
representing shared circulation between cancer cells, their secreted factors, and muscle cells.  
 
2.3. Role of IL-15 
  Gene and protein markers associated with cancer-induced loss of body weight, 
increased inflammation, and skeletal muscle protein breakdown show that pathways of fatigue 
often accompany cancer cachexia [15]. One such biomarker is IL-15, which is a recently 
discovered four-helix bundle cytokine [4]. Commonly, IL-15 has been investigated concerning its 
role in inflammation and its regulation in immune homeostasis [33]. It has been regarded as both 
pro-inflammatory and anti-inflammatory through its activation of Natural killer (NK) cells that 
display an increased immune response to invading pathogens [33, 34]. IL-15 has been seen as a 
potent inflammatory chemokine with potential in preventing and/or treating obesity and other 
metabolic disorders [35, 36]. 
  Previous data collected in our laboratory using a transgenic mouse model lacking the gene 
for IL-15Rα suggest that IL-15 promotes mitochondrial biogenesis [3]. IL-15Rα is a highly 
specific non-signaling binding receptor for IL-15 and is thereby one of its primary regulators. 
Upon translation, the IL-15 gene encodes for two distinct isoforms of IL-15 including, a short 
21-amino acid and a long 48 amino acid signal peptide [37]. It is the long IL-15 isoform that 
binds to IL-15Rα, allowing for the secretion of the cytokine-receptor complex from skeletal 
muscle [37].  However, even though free IL-15 secretion from the cell occurs, the binding 
between IL-15 and its receptor IL-15Rα promotes an elevated ability for subsequent IL-15 signal 
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transduction [38].  
  The use of a transgenic mouse model, that specifically overexpresses IL-15, has been 
shown to display an enhanced endurance capacity and to increase the expression of 
mitochondrial associated factors and mitochondrial mass [3, 4, 39]. An increased expression of 
myosin heavy chain (MHC-1) and troponin 1 mRNA isoform expression in the muscle tissue of 
the IL-15 transgenic mice is credited to this oxidative phenotype [39]. Further, Quinn et al. [35] 
reported increased myofibrillar protein accumulation in IL-15 overexpressing myogenic cells, 
along with hypertrophied myotube morphology. These data provide evidence for the positive role 
of IL-15 in facilitating an elevated substrate utilization capacity in skeletal muscle through its 
action in different molecular pathways [36, 37, 40]. However, there is still no clear distinction of 
the molecular mediators responsible for these effects. Thus, there is a need to further study the 
different signaling pathways that are downstream of IL-15 action, with some of them being shown 
in Figure 2.  
 
 
 
 
11 
 
Figure 2: Sources of IL-15 and Signaling Pathways implicated with IL-15. 
Above image from Ye [41] depicts the multiple cellular sources and signaling pathways of IL-15 
to illustrate the diverse functions of IL-15.  
 
 
2.4 JAK/STAT pathway 
  The Janus kinase activation of signal transducer and activator of transcription proteins 
(JAK/STAT) signaling pathway is one of the most commonly studied pathways that is downstream 
of IL-15 action [12, 41]. The JAK/STAT pathway is a simple membrane-to-nucleus pathway 
whereby extracellular factors control gene expression (Figure 3) [42]. Activation of the receptor-
associated JAKs occurs with the binding of the ligand, causing auto-phosphorylation on the 
intracellular tails, thereby making docking sites for the cytoplasmic transcription factors, STATs, 
to bind and become phosphorylated [42]. Activated STAT directly binds to DNA and has the 
ability to regulate gene expression [43, 44]. Overall, the JAK/STAT signaling pathway has been 
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found to occur in virtually every tissue of the body, giving it the ability to effect energy 
metabolism in many cell types due to its large number of intracellular functions [45].    
                       
 
Figure 3: Mechanism of JAK/STAT Pathway. 
The figure above from O’Shea et al. [44] shows the mechanism by which the JAK/STAT signaling 
pathway plays a role in gene expression through its communication that starts from 
transmembrane receptors to the nucleus. 
 
 
  The JAK/STAT signaling pathway has multiple mediators and isoforms that correspond to 
the distinct in vivo roles of this cascade. There are four JAKs: JAK1, JAK2, JAK3, and TYK2, 
which can selectively bind various receptor chains, while seven mammalian STAT family 
members, namely STAT1, STAT2, STAT3, STAT4, STAT5a, STAT5b, and STAT6 have been 
identified [42]. Specific to IL-15, the mechanism begins with the binding of the IL-15 to the IL-15 
receptor complex, which cause the auto-phosphorylation of the JAK isoforms (JAK1 and/or 
JAK3), further inducing the phosphorylation of STAT3 and/or STAT5 [41]. Since different 
cytokines have the ability to activate different STATs, the underlying mechanisms by which gene 
transcription is affected can be explained using new technologies that determine transcription 
factor binding, genome wide assessments, and using knockout mice models. 
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  Signaling through STAT3 has been reported to increase the acute phase response gene 
expression in the liver [46]. The acute phase response is a generalized response of the innate 
immune system, consisting of a series of specific physiological reactions caused by the up-
regulation (up to several thousand-fold) of some 40 genes upon stimulation [47, 48]. Elevations in 
acute phase response proteins in the serum have been linked to cancer cachexia [49–51]. Further, 
Silva et al. reported that the activation of pSTAT3 in C2C12 myotubes induces the activation of 
two different proteolytic pathways in the muscle – caspase 3, and the MAFbx/Atrogin-1 and 
MuRF-1 pathways [8]. Finally, STAT3 activation has also been reported to enhance tumorigenesis, 
metastasis, and immune system suppression, factors all leading to its link to cancer cachexia [52]. 
  
 
2.5 Reactive Oxygen Species (ROS) and Cancer 
  Reactive oxygen species (ROS), are radicals, molecules or ions that exhibit a single 
unpaired electron in their outermost shell of electrons and therefore, are highly reactive [53]. 
ROS can be generated endogenously during mitochondrial oxidative metabolism through leaking 
of electrons as they pass through the different mitochondrial complexes of the electron transport 
chain (Figure 4A) [54]. Along with mitochondria, another major site of endogenous ROS 
generation are peroxisomes [55]. However, ROS production is also common through interactions 
within exogenous sources in the body such as cytokines, xenobiotic, and bacterial compounds 
[54]. 
  An increase in ROS levels combined with a decrease in the cells natural antioxidant 
machinery leads to oxidative stress which results in the detrimental damage of proteins, nucleic 
acids, and lipids by ROS (Figure 4B) [54, 56, 57]. Single-stranded and double-stranded DNA 
breaks can be evoked through the reaction of ROS with nucleic acids causing a disruption 
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between the nitrogenous and sugar phosphate backbones [58]. In the case of lipids, the reaction 
between ROS and polyunsaturated fatty acids can induce lipid peroxidation which can lead to 
alteration of the membrane by-layers [59]. Free radicals have also been reported to cause various 
forms of oxidative modifications in proteins [60]. Protein carbonylation is one such modification, 
which has been shown to occur commonly at the side chains of four distinct amino acids - 
proline, lysine, threonine, and arginine [60]. This irreversible modification is clinically relevant 
since this carbonylation leads to the tagging of proteins for proteasomal degradation, and is thus 
considered one of the major hallmarks of oxidative stress-related disorders [60, 61] 
  ROS participation is seen in multiple pathological conditions including malignancies, 
diabetes, atherosclerosis, aging, and neurological degenerative diseases [54, 62, 63]. Elevated 
levels of ROS are seen in mostly all of the different types of cancers and have shown to promote 
pro-tumorigenic signaling, cancer cell proliferation, and tumor development and progression [64]. 
However, ROS have now been implicated to play a dual role in cancer and have also been shown 
to promote anti-tumorigenic signaling leading to oxidative stress-induced cancer cell death [65]. 
To study the mechanisms, in vitro studies use different types of ROS to observe and study the 
many aspects of ROS activity. Hydrogen peroxide (H2O2) is a widely used ROS that induces 
oxidative stress in cells and Li et al. investigated the effects of IL-15 as a potential protective 
mechanism against this H2O2 mediated oxidative stress in C2C12 myoblasts [66]. Interestingly, it 
was found that preincubation with IL-15 reduced the activities of intracellular creatine kinase and 
lactate dehydrogenase, enzymes involved in various metabolic pathways, thereby decreasing the 
ROS overload [66]. They also reported an upregulated mRNA expression level of uncoupling 
protein 3 (UCP3) and IL-15, eluding to enhanced protection of the mitochondrial networks.   
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 Figure 4: Souces of ROS production and Signaling Pathways implicated with ROS. 
Above images from Liang et al [56] show the different intracellular sources of ROS and the 
signaling pathways they affect. Panel A shows that the greatest amount of ROS production 
occurs at complexes I and III of the electron transport chain during oxidative phosphorylation. 
An additional source of intracellular ROS (O2-) is NADPH oxidase, shown at the top right of 
panel A. Panel B shows the different signaling cascades that ROS can induce that lead to 
damage of proteins, nucleic acids, and lipids. 
 
 
2.6 Background Summary and Significance  
  Taken as a whole, the current literature is not able to provide the direct mechanism 
through which cancer cachexia takes place. While a wide variety of pathways have been 
implicated to play a role in muscle protein degradation and inhibition of muscle growth, the 
effects of IL-15, a myokine, have yet to be fully investigated. It is expected that this research will 
provide a better understanding of the changes in the JAK3/STAT3 signaling pathway that is 
downstream of IL-15 binding. The use of an IL-15TG mouse model that overexpresses IL-15 
will allow us to observe its downstream effects on the mediators of the JAK3/STAT3 pathway in 
the presence of cancer cell-secreted factors. Since our lab has previously shown IL-15 to 
promote a pro-oxidative muscle phenotype, and rescue fatigue in mouse models [3], we were 
interested in seeing its role in a cancer-induced model of muscle dysfunction. We first 
successfully established a working ex-vivo model using a 25% dilution of conditioned media 
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from an established MDA-MB-231 breast cancer cell line, and then we examined the functional 
output of a whole muscle exposed to conditioned media. This gave us the ability to determine the 
relationship between muscle function and activation of the mediators of molecular pathways. 
This served as a translational tool since it simulated an in-vivo environment seen in tumor-
bearing animals through the models’ common circulation between cancer cell-derived factors 
and muscle tissue. While this project only examined the JAK3/STAT3 pathway and used 
conditioned media from a specific breast cancer cell line, it was anticipated that this model can 
be used for examining additional signaling pathways using conditioned media from various 
cancer cell lines. For future work, therapeutic remedies and feasible dosing of IL-15 can also be 
tested since this model will serve as a translational tool as it can represent an in vivo scenario of 
shared circulation.  
 
 
CHAPTER 3. 
 
Methods 
 
 
3.1 Study Design Overview  
  The project was completed in Dr. Emidio Pistilli’s laboratory at West Virginia 
University. We used two different mice models - WT mice (strain C57BL/6J) and transgenic 
mice IL-15TG, which over express Interleukin-15 (measurable levels of IL-15 protein expression 
are approximately 6-fold greater in transgenic sera, in comparison to WT mice [67]). Each group 
was exposed to two different conditions: 25% diluted conditioned media (CM), and 25% diluted 
unconditioned media (UCM) prior to functional testing and molecular experiments. All of the 
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conditioned and unconditioned media was collected from Dr. Elena Pugacheva’s laboratory that 
is located at the West Virginia University Cancer Institute.   
 
3.2 Mice Models 
  C57BL/6J WT mice were purchased from the Jackson Laboratory (n=18). The age 
matched WT mice were then randomly assigned to the two different groups: 25% unconditioned 
media (n=9), and 25% conditioned media (n=9). IL-15TG mice were purchased from Jackson 
Laboratory (n=20) and were bred to yield IL-15TG pups and littermate controls (no transgene 
present). The IL-15TG mice (both males and females) were then randomly assigned to four 
different groups: littermate control 25% unconditioned media (TG -/- n=5), transgenic 25% 
unconditioned media (TG +/- n=5), littermate control 25% conditioned media (TG -/- n=5), and 
transgenic 25% conditioned media (TG +/- n=5). Mice were housed in the AAALAC approved 
animal vivarium at West Virginia University at 22°C under a 12:12-h light-dark cycle and 
received food and water ab libitum. The Institutional Animal Care and Use Committee at West 
Virginia University approved all animal experiments prior to the start of the project. 
 
3.3 Animal Care 
  All mice were housed in the animal vivarium located in the Robert C. Byrd Health 
Sciences Center (HSC) of West Virginia University School of Medicine. The animal vivarium 
maintains compliance with the NIH and the Institutional Animal Care and Use Committee 
guidelines. Animals were maintained in a pathogen-free environment, received adequate food 
and water and were attended to by a full-time veterinary doctor and support staff. 
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3.4 Media Collection  
  The conditioned media was collected through the cultivation of the breast cancer cell line, 
MDA-MB-231. The cell culture procedures were performed in the Pugacheva lab under the same 
sterile conditions. The cells were maintained in high glucose DMEM supplemented with 10% 
FBS to maintain active proliferation. Similar to the CM, the UCM comprised of DMEM and was 
plated at the same time and was exposed to identical conditions including incubation time, 
temperature and localization in the same incubator. The confluency of the cells was noted to 
ensure that there were no confounding errors. After the cells reached a confluency of greater than 
90%, the media was removed from the plate and was transported to the Pistilli lab where it was 
filtered using a 70micron filter and then placed into 1mL tubes. The vials were immediately flash 
frozen in liquid nitrogen and stored in the -80 Celsius freezer until further use.  
 
3.5 Stock Preparation  
  Prior to the surgical procedures, the two different chambers of the commercially available 
muscle physiology system (Aurora Scientific, Ontario, CA) were filled with the required level of 
media. The two tested conditions for the media were a) 25% DMEM in Ringers Solution 
(forming our UCM) and b) 25% Conditioned Media in Ringers Solution. DMEM is a medium 
for culturing different cell lines that contains amino acids, vitamins, and supplementary 
components (including Fetal bovine serum, growth factors, cytokines, matrix proteins, ATP, 
glucose, calcium etc.). Ringers Solution is made using 100 mM NaCl, 4.7 mM KCl, 3.4 mM 
CaCl2, 1.2 mM KH2PO4, 1.2 mM MgSO4, 25 mM HEPES, and 5.5 mM D-glucose and distilled 
water. On the day of the experiment, the media was thawed in the water bath maintained at 37°C 
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and mixed in with the Ringer solution that maintained a pH of 7.40 to reach a dilution of 25%. 
 
3.6 Mouse Surgery 
  On the day of data collection, each mouse was removed from the animal vivarium at 
West Virginia University and was brought to Pistilli Lab. Following the experimental set up, the 
mouse was placed under full anesthesia by breathing 4% isoflurane delivered through a nose 
cone at a flow rate of 1 L·min-1. The hind limbs of the mouse were taped down to expose the 
lateral side of the leg, and the Extensor Digitorum Longus (EDL) muscle was removed with both 
proximal and distal tendons intact (Figure 5). EDL muscles were immediately transferred to an 
oxygenated tissue bath that contained the Ringers solution maintained at 22°C. While in the bath, 
nylon sutures were attached to the tendons. Dr. Emidio Pistilli performed all the surgical 
procedures, while I assisted during these procedures. Subsequently, the mouse was euthanized by 
cervical dislocation, while still under anesthesia. 
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Figure 5: Extensor digitorum longus (EDL) muscle isolation. 
This figure demonstrates the EDL muscle isolation from a mouse hindlimb. Panel A shows the 
exposed hindlimb of an adult mouse with the arrows indicating the distal patella tendon and the 
proximal tendon attachments in the foot. Panel B shows the anatomical position of the Tibialis 
Anterior (TA) muscle and the EDL muscle. Panel C shows the EDL muscle being pulled 
superiorly to expose the distal tendon, while the proximal tendon is held in place with forceps. 
Panel D shows the tendon of the EDL being cut to release the EDL muscle [68].  
 
 
 
3.7 Muscle Function Analysis of EDL muscle in C57BL/6J WT mice, IL-15TG littermate 
control mice and IL-15TG overexpressing IL-15  mice. 
  For the purpose of ex vivo muscle stimulation, a commercially available muscle 
physiology system (Aurora Scientific, Ontario, Canada) was used to assess the functional output 
of the EDL muscle in the different conditions. To remain consistent, the right EDL was set up in 
the chamber with the force transducer plate while the left EDL was set up in another incubation 
chamber in which the muscle was not stimulated (Figure 6). Both chambers were supplemented 
95%/5% O2/CO2. For the EDL muscle that underwent contractions, a preset protocol that 
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induced 3600 twitch contractions was selected. This protocol was repeated two consecutive 
times, to induce a total of 7200 twitch contractions. There was no resting period between the two 
consecutive protocol runs. The protocol duration was 3 hours and 10 minutes, which equated to 
11,200 seconds. Therefore, we got a contraction every 1.6 seconds 
(11200seconds/7200contractions). Once the protocol was completed, the muscles were removed 
from the chambers, the sutures were removed and the muscles were placed into labeled tubes. 
Immediately following that the vials were flash frozen in liquid nitrogen and stored in the -80 
Celsius freezer until further use to assess molecular changes.  
 
 Figure 6: Aurora Scientific muscle physiology system. 
This figure shows the physiology system - Aurora Scientific, Ontario, Canada, used to assess the 
functional output of the EDL muscle in the different conditions. Panel A shows the chamber in 
which the muscle exposed to media without any stimulations was placed in, whereas Panel B 
shows the chamber that was used to expose the muscle to media and used to test for function. 
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3.8 pH Measurement 
  The pH of the specific media used was recorded at different time points during the 
protocol using the Thermo Scientific Orion Dual Star pH reader. The pH in the media was 
recorded at the start of the experiment for both the chambers, which was analogous. Once the 3 
hour and 10 minute protocol was completed, the media was collected from the separate chambers 
and the pH was measured and recorded for both, the stimulated and unstimulated media.  
 
3.9 Protein Quantification  
  To assess molecular changes through protein detection, the muscles that were previously 
flash frozen after functional testing were thawed and homogenized in preparation for western 
blot analyses. The entire EDL muscle was homogenized in RIPA buffer (1% sodium 
deoxycholate, 1% Triton x-100, 150 mM NaCl, 5 mM EDTA, 10 mM Tris; pH 7.4), containing a 
phosphatase inhibitor and a protease inhibitor cocktail (Sigma-Aldrich, St. Louis, MO). 
Following homogenization, the protein concentrations were measured using the BioRad DC 
protein assay (BioRad, Hercules, CA).  
 
3.10 Western Blot 
  To assess protein content, protein lysates were resolved using 4-12% gradient polyacrylamide 
gels (PAGE) under denaturing conditions. Prior experience for successfully running PAGE gels had been 
achieved under the guidance of Dr. Yehenew Agazie at West Virginia University. Different key 
intermediates in the JAK3/STAT3 pathway were quantified. The protein concentrations were determined, 
and 20µg of protein was added to make a total of 30µL of loading samples, which were then loaded into 
each well of a 4-12% gradient polyacrylamide gel (Invitrogen, Carlsbad, CA) and the gel was run at 120 
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volts for 1 hour and 30 minutes. The proteins were transferred to a nitrocellulose membrane at 4°C for 1 
hour at 25 volts in transfer buffer. Blocking non-specific protein binding was achieved by incubating the 
membranes in 5% nonfat milk in Tris-buffered saline containing 0.05% Tween 20 (TBST) for 1 hour. The 
membranes were then incubated overnight with gentle rocking at 4°C in appropriate primary antibodies of 
1:1000 dilution. Following the overnight incubation, the membranes underwent 3x10 minute washes, 
followed by incubation in the appropriate secondary antibody (Invitrogen rabbit anti-mouse IgG-HRP or 
Invitrogen goat anti-rabbit IgG HRP, diluted 1:2000) at room temperature for 1 hour with gentle rocking. 
Membranes then underwent another 3x10 minute washes prior and the signals were developed by using 
enhanced chemiluminescence (Pierce ECL Western Blotting Substrate) that were visualized by a GE 
Amersham Imager 600, a high resolution imaging system to identify the band intensity. The digital 
images were quantified with Image J software (NIH) and the intensity of each band was normalized to 
GAPDH, which was from the same sample and on the same gel. Each membrane was stripped and re-
probed between phospho-STAT3 probe and total-STAT3 probe. The data were expressed as arbitrary 
units. 
 
3.11 Protein Carbonyl Assay 
  To assess if media induced oxidative stress induced any protein oxidation, the OxiSelect 
Protein Carbonyl Fluorometric Assay was used. The protein carbonyls in the different protein 
samples (1-10 mg/mL) were first derivatized with Protein Carbonyl Fluorophore (PCF). The 
PCF and protein carbonyl were bounded in a 1:1 ratio. Following this, the proteins were TCA 
precipitated and the free PCF was removed through acetone washes. The protein pellet was then 
dissolved in GuHCL, and the absorbance of the protein-fluorophore product was measured with 
a 485/538nm filter [69]. Lastly, the concentration of the protein carbonyl was calculated.  
 
 
 
 
24 
 
3.12 Data Analysis  
  Statistical analyses were performed using GraphPad Prism 6 software. All data points 
collected from the twitch protocol were transported to excel prior to the software. Each 
individual group had a sample size of 5 muscles each (n=5). Data are reported as mean ± SEM, 
using two-way ANOVA statistical analyses. A p value of ≤0.05 was considered to be statistically 
significant. 
 
	  
CHAPTER 4. 
Results 
 
4.1 Evaluation of Extensor Digitorum Longus (EDL) muscle function using different 
protocols.  
  Preliminary studies to examine different protocols and their effect on inducing 
differences in mRNA levels of IL-6 were conducted in our lab. Table 1 shows the various 
conditions tested on extensor digitorum longus muscles (EDL) from C57BL/6J strain mice using 
a commercially available muscle physiology system (Aurora Scientific, Ontario, Canada). All 
functional procedures were performed in 100% Ringers Solution (100 mM NaCl, 4.7 mM KCl, 
3.4 mM CaCl2, 1.2 mM KH2PO4, 1.2 mM MgSO4, 25 mM HEPES, and 5.5 mM D-glucose, 
distilled water). Figure 7 and Figure 8 show the results of the semi-quantitative PCRs used to 
test the different conditions explained in Table 1. 
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Table 1: Different Protocol Conditions. 
The table below provides the specific details of the individual conditions used for analyzing 
stimulation of EDL muscles. Both left and right EDLs from the same mouse were tested with one 
serving as a control and the other being tested under the specific condition.  
   
Stimulation of EDL Muscles for Analysis under Different Protocol 
Conditions 
CONDITION 1 Control Normal Protocol  EDL 1 – Twitch (1Hz), tetanus (120Hz), fatigue  
 
EDL 2 – Sit at Lo in oxygenated Ringer for 
same time 
CONDITION 2 Control Normal Protocol 
+ 30 minute rest 
EDL 1 – Twitch (1Hz), tetanus (120Hz), 
fatigue, 30 minute rest 
 
EDL 2 – Sit at Lo in oxygenated Ringer for 
same time 
CONDITION 3 Control Normal Protocol 
+ 60 minute rest 
EDL 1 – Twitch (1Hz), tetanus (120Hz), 
fatigue, 60 minute rest 
 
EDL 2 – Sit at Lo in oxygenated Ringer for 
same time 
CONDITION 4 Twitch to get to Lo, 1 
twitch/ second for 60 
minutes, rest in bath for 
same time (stimulate at 
1Hz/60 min) 
EDL 1 – 1 Twitch (1Hz) per second for 60 
minutes, rest in bath for same time  
EDL 2 – Sit at Lo in oxygenated Ringer for 
same time 
CONDITION 5 Twitch to get to Lo, 1 
tetanus/ minute for 60 
minutes, rest in bath for 
same time 
EDL 1 – 1 tetanus/ minute (120Hz) for 60 
minutes, rest in bath for same time 
EDL 2 – Sit at Lo in oxygenated Ringer for 
same time 
CONDITION 6 Twitches to get to Lo, 
then repeated twitches 
every 3 seconds for 3 
hours + rest in bath for 2 
hours  
EDL 1 – Twitches (1Hz) every 3 seconds for 3 
hours or until >50-70% loss in force + rest in 
bath for 2 hours 
EDL 2 – Sit at Lo in oxygenated Ringer for 
same time 
CONDITION 7 Twitches to get to Lo, 
then repeated tetanus 
once per  minute for 3 
hours + rest in bath for 2 
EDL 1 – repeated tetanus (120Hz) once per 
minute for 3 hours or until >70% loss in force + 
rest in bath for 2 hours 
EDL 2 – Sit at Lo in oxygenated Ringer for 
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hours same time 
CONDITION 8 Incubation with elevated 
temperature (37°C) for 2 
hours  
EDL 1 – Incubation with elevated temperature 
(37°C) for 2 hours 
 
EDL 2 – Incubation with normal temperature 
(22°C) for 2 hours 
CONDITION 9 Incubation with 
depressed temperature 
(9-10°C) for 2 hours 
EDL 1 – Incubation with depressed temperature 
(9-10°C) for 2 hours 
EDL 2 – Incubation with normal temperature 
(22°C) for 2 hours 
 
 
 
 
Figure 7: PCR depicting mRNA levels of IL-6. 
This semi-quantitative PCR shows the mRNA levels of IL-6 obtained from the EDL muscles of 
muscles placed in the following conditions: condition 1 (EDL 1 and EDL 2), condition 2 (EDL 3 
and EDL 4), condition 3 (EDL 5 and EDL 6), condition 4 (EDL 7 and EDL 8), and condition 5 
(EDL 9 and EDL 10). Increases in mRNA levels were observed in EDL muscles 7 and 9 
corresponding to condition 4 (twitch (1Hz) allowed to get to Lo, 1 tetanus(120Hz)/ minute for 60 
minutes) and condition 5 (twitch (1Hz) to get to Lo, 1 tetanus (120Hz)/ minute for 60 minutes), 
respectively.  
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Figure 8: PCR depicting mRNA levels of IL-6. 
This semi-quantitative PCR shows the mRNA levels of IL-6 obtained from the EDL muscles 
placed in the following conditions: condition 6 (EDL 1 and EDL 2), condition 7 (EDL 3 and 
EDL 4), condition 8 (EDL 5 and EDL 6), and condition 9 (EDL 7 and EDL 8). Increases in 
mRNA levels were observed in EDL muscles 1 and 2 corresponding to condition 6 (Twitches 
allowed to get to maximal twitch response (i.e., Lo), then repeated twitches (1Hz) every 3 
seconds for 3 hours or until >50-70% loss in force + rest in bath for 2 hours). 
 
 
  We found that 3 hours of twitches (1Hz) produced a larger IL-6 response than the 3-hour 
tetanus (120Hz) (Figure 8). These data suggested that maximal change in the mRNA levels was 
observed when the protocol is run under condition 6 (Twitches allowed to get to maximal twitch 
response (i.e., Lo), then repeated twitches (1Hz) every 3 seconds for 3 hours or until >50-70% 
loss in force + rest in bath for 2 hours). Therefore, we decided to address Specific Aim #1 of the 
project, which is to determine the effects of 25% diluted conditioned media on muscle function 
in an ex vivo model, using condition 6 for our experimental protocol.   
 
4.2 Determination of Conditioned Media Composition for Muscle Incubation 
  To determine what percentage of conditioned media (CM) from the culture MDA-MB-
231 cell line will be appropriate for the purpose of the model, semi-quantitative PCR for Muscle 
atrophy F-box (MAFbx)/Atrogin-1, Muscle RING finger 1 (Murf-1), and Interleukin (IL-6) were 
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performed. Murf-1 and Atrogin-1 are two muscle-specific E3 ubiquitin ligases that have shown 
to be transcriptionally increased in skeletal muscles under atrophy-inducing conditions [70]. On 
the other hand, IL-6 is suggested as a potential mediator in cancer cachexia, which is seen in the 
acute phase of inflammation associated in cancer cachexia [71]. Consistent with previously 
established work, we observed an increase in mRNA levels in both, Murf-1 and Atrogin-1, 
markers of muscle atrophy using 25% diluted CM in comparison to the samples exposed to 
either 10% diluted CM or control media (Figure 9).  
 
 
 
 
 
Figure 9: PCR depicting mRNA levels of Murf-1, Atrogin-1, and IL-6 using different CM 
percentages. 
This semi-quantitative PCR shows the mRNA levels of three biomarkers; Atrogin1, Murf1, and 
IL-6 in EDL muscles exposed to control media, EDL muscles exposed to 10% diluted CM, and 
EDL muscles exposed to 25% diluted CM. Changes were observed in Atrogin1 and Murf1 in the 
samples exposed to 25% diluted CM in comparison to the samples exposed to either 10% diluted 
CM or control media.   
 
 
4.3 Effect of 25% diluted CM on Contractile Data of muscles exposed to secreted factors 
from the MDA-MB-231 cell line 
To test the muscle function in this cancer-induced model of muscle dysfunction, we measured 
muscle force in different mice models – C57BL/6J WT mice, IL-15TG, overexpressing IL-15, 
and IL-15TG littermate controls. Figures 10 –13 are representative of the results from the 
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experimental protocol. Muscles were stimulated using 1 twitch every 1.6 seconds for 3 hours and 
10 minutes giving us a total of 7200 contractions. The EDL Fatigue Curves represent the relative 
percentage of fatigue seen across all groups and media exposure. We then calculated the total 
aggregate force of the entire protocol time to get the Area Under the Curve (AUC) graphs, which 
can be equated as the total force output during the protocol.  
  Figure 10 represents the EDL Fatigue curve and AUC for the WT and TG littermate 
control groups exposed to either CM or UCM. This validated our assumption of seeing no 
statistical difference between these two groups. With the results of this control experiment, we 
decided to analyze TG (IL-15TG) and TG controls for further muscle contractile analysis. A 
combined analysis of all three groups (WT, TG, and TG controls) is reported in the 
supplementary data as Supplementary Figure 1 and Supplementary Figure 2, respectively.  
  Figure 11 represents the EDL Fatigue curve and AUC for the TG and TG Control groups 
exposed to the two media types (CM vs. UCM). No statistical differences are seen in either of 
the groups. We were also interested in comparing all three genotypic groups relative to either 
CM or UCM to see any statistical significance or trend. Figure 12 and Figure 13 report these 
analyses. No statistical significance were seen in either of the analyses. We concluded that acute 
exposure to conditioned media produces no significant effect on muscle fatigue.  
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Figure 10: EDL Fatigue curve and Area Under the Fatigue Curve for WT and TG Control. 
Panel A shows the EDL fatigue curves for conditions in the UCM WT, CM WT, UCM CON, and 
CM CON groups. No statistical differences were seen between any of the groups. Panel B shows 
the EDL Total Area Under the Fatigue Curves (mN*S) for conditions in the UCM WT, CM WT, 
UCM CON, and CM CON groups. No statistical differences were seen between any of the group. 
 
 
 
 
Figure 11: EDL Fatigue curve and Area Under the Fatigue Curve for TG and TG Control. 
Panel A shows the EDL fatigue curves for conditions in the UCM TG, CM TG, UCM CON, and 
CM CON groups. No statistical differences were seen between any of the groups. Panel B shows 
the EDL Total Area Under the Fatigue Curves (mN*S) for conditions in the UCM TG, CM TG, 
UCM CON, and CM CON groups. No statistical differences were seen between any of the group. 
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Figure 12: EDL Fatigue curve and Area Under the Fatigue Curve for all groups exposed to 
25% diluted CM  
Panel A shows the EDL fatigue curves for all three groups (WT, TG, and CON) exposed to 25% 
diluted CM. No statistical differences were seen between any of the groups. Panel B shows the 
EDL Total Area Under the Fatigue Curves (mN*S) for all three groups (WT, TG, and CON) 
exposed to 25% diluted CM. No statistical differences were seen between any of the groups. 
Figure 13: EDL Fatigue curve and Area Under the Fatigue Curve for all groups exposed to 
25% UCM  
Panel A shows the EDL fatigue curves for all three groups (WT, TG, and CON) exposed to 25% 
diluted UCM. No statistical differences were seen between any of the groups. Panel B shows the 
EDL Total Area Under the Fatigue Curves (mN*S) for all three groups (WT, TG, and CON) 
exposed to 25% diluted UCM. No statistical differences were seen between any of the groups. 
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4.4 Protein Carbonyl Concentrations to measure for Oxidative Stress 
  To assess if oxidative stress of media treatments induced muscle protein oxidation, the 
OxiSelect Protein Carbonyl Fluorometric Assay was used. We decided to combine all the 
genotypic samples together to analyze for carbonyl concentrations relative to either stimulation 
(stimulated vs. unstimulated) and media type (CM vs. UCM). Figure 14 is represntative of these 
analyses. No statistical differences were seen between any of the groups. We concluded that 
acute exposure to conditioned media cell-secreted factors, which we hypothesized would lead to 
oxidative stress did not induce any significant protein carbonylation between the different 
groups.  
 
  
Figure 14: Carbonyl Concentration (nmol/mg) in all groups relative to different conditions. 
Panel A shows the Carbonyl concentrations present in the different groups (WT, TG, and CON) 
relative to muscle stimulation (stimulated vs. unstimulated). No statistical differences were seen 
between any of the groups. Panel B shows the Carbonyl concentrations present in the different 
groups (WT, TG, and CON) relative to the media type (CM vs. UCM). No statistical differences 
were seen between any of the groups. 
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4.5 Measurement of pH changes  
  Another factor implicated for the development of muscle fatigue is the presence of excess 
protons (H+) that arise as a by-product of glycolysis [70, 71]. To assess if the pH change was 
significantly different between the media type and stimulations, we noted the pH of the media 
prior to the start of the protocol and at the end of the protocol in each condition for the samples 
in the Wild Type group. The percentage change was then put into our statistical model and 
Figure 14 is represntative of these analyses. No statistical differences were seen between any of 
the groups. Since contractile activity has been shown to lead to an acidotic state that has further 
been related to muscle fatigue [72, 73], we concluded that our sample size was too small to show 
significance as we only measured pH changes in the WT group (n=8).   
  
Figure 15: Measurement of pH changes in the Wild Type group.  
Figure 15 shows the pH changes that were measured at two different time points - prior to the 
start of the experiment protocol and at the end of the protocol in the Wild Type group. Panel A 
shows the grouped pH change comparing media type (CM vs. UCM), while Panel B shows the 
grouped pH change comparing muscle stimulation (stimulated vs. unstimulated). No statistical 
differences were seen between any of the groups. 
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4.6 Effect of 25% diluted CM on Contractile Data of muscles following 2-hour Extended 
Exposure 
  Towards the end of the project, with only two mice left in both our TG and TG Control 
colonies, we decided to alter our protocol to extend the exposure time of the MDA-MB-231 cell-
secreted factors on the muscles. Recent studies have reported an effect on signaling pathways by 
CM only after a chronic exposure [9, 14]. Based on this evidence, we decided to assign each of 
the 4 mice to the 4 different groups (CM TG, UCM TG, CM CON, and UCM CON). We used 
the same functional output protocol, but added an additional 2-hour pre-incubation in the 
respective media and chamber. A continuous line of 100% oxygen was supplied to each muscle. 
Since we only had one sample in each group, no statistical analyses were performed. However, a 
graphical comparison and representation between the mean of the fatigue curves of the 
respective groups with the muscle fatigue curve of the individual samples with Extended 
Exposure are presented in Figures 16 and 17. The blue fatigue curves represented in Panel A and 
C of Figure 16 are indicative of the mean fatigue curves of the TG mice and TG Control mice 
exposed to UCM in the experiments that were already conducted without extended exposure, 
while the orange fatigue curves are indicative of the fatigue curves of the single muscles that 
were pre-incubated for an additional two hours prior to the start of the fatigue protocol. 
Similarly, the blue fatigue curves in Panel A and C of Figure 17 are indicative of the mean 
fatigue curves of the TG mice and TG Control mice exposed to CM in the experiments that were 
already conducted without extended exposure, while the orange fatigue curves are indicative of 
the fatigue curve of the single muscles that were pre-incubated for an additional two hours prior 
to the start of the fatigue protocol. We observe a shift in the EDL fatigue curve of the single 
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muscles (orange fatigue curve) to the bottom left in all 4 samples relative to their groups. This 
suggests that the additional pre-incubation may in fact be causing muscle dysfunction via 
exposure top cancer cell-secreted factors. Similarly, we observed a decrease in Area Under the 
Fatigue Curve for all of the samples, coinciding with the graphs, thereby showing a lower total 
aggregate force.  
 
 
 
Figure 16: EDL Fatigue curves and Area Under the Fatigue Curve for UCM CON and 
UCM TG groups exposed to their respective Extended Exposure Sample 
Panel A shows the EDL fatigue curves for the mean UCM CON group and the Extended 
Exposure sample. Panel B shows the EDL Total Area Under the Fatigue Curves for the mean 
UCM CON group and the Extended Exposure sample. Panel C shows the EDL fatigue curves for 
the mean UCM TG group and the Extended Exposure sample. Panel D shows the EDL Total 
Area Under the Fatigue Curves for the mean UCM TG group and the Extended Exposure 
sample. 
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Figure 17: EDL Fatigue curves and Area Under the Fatigue Curve for CM CON and CM 
TG groups exposed to their respective Extended Exposure Sample 
Panel A shows the EDL fatigue curves for the mean CM CON group and the Extended Exposure 
sample. Panel B shows the EDL Total Area Under the Fatigue Curves (mN*S) for the mean CM 
CON group and the Extended Exposure sample. Panel C shows the EDL fatigue curves for the 
mean CM TG group and the Extended Exposure sample. Panel D shows the EDL Total Area 
Under the Fatigue Curves (mN*S) for the mean CM TG group and the Extended Exposure 
sample. 
 
 
4.7 Western Blot Analysis of pSTAT3 and total STAT3 
Western blot analyses were performed on WT and TG samples exposed to the different 
conditions (CM stimulated, CM unstimulated, UCM stimulated, and UCM unstimulated). For 
protein quantification, all of the signals from the proteins of interest (pSTAT3 and STAT3) were 
first normalized to GAPDH, which was probed on the same gel. Figure 18 represents the western 
blots for all of the samples in the WT group. No significance was observed in either of the 
samples (WT group, n=16). However, a statistical significance (p<0.05) was seen in 
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phosphorylated STAT3 to total STAT3 in the stimulated CM and the stimulated UCM conditions 
in the TG samples (TG group, n= 16). Since the samples in both groups were combined, we ran 
additional analyses on the individual gels (n=8), which are represented as Supplementary Figures 
4 through 8. No significant differences were seen in either of the individual analyses in both WT 
samples and TG samples.   
  
 
 
 
Figure 18: Quantification of pSTAT3 and STAT3 in combined analysis (n= 16) for the WT 
samples. 
Quantification of the WT samples showed no statistical significance in phosphorylated STAT3 to 
total STAT3. 
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Figure 19: Quantification of pSTAT3 and STAT3 in combined analysis (n= 8) for the TG 
samples.  Quantification of the blot showed statistical significance in phosphorylated STAT3 to 
total STAT3 in the CM stimulated condition. * represents a significant difference with p<0.05. 
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Chapter 5. 
Discussion 
  The muscle wasting associated with cancer cachexia is related to reduced strength and 
muscle weakness [76]. While a loss of muscle mass is attributed to the severe fatigue 
experienced by some patients, it has been shown that cancer-induced muscle fatigue can occur 
without loss of muscle mass [1]. Through this research, we wanted to develop an ex-vivo model 
that would mirror a cancer-induced model of muscle dysfunction. By achieving this, we intended 
to study the effects of Interleukin-15 (IL-15) on the induced cachectic conditions in extensor 
digitorum longus (EDL) muscles and also report the molecular effects of IL-15 on mediators of 
the JAK-STAT pathway. 
  Stimulation through exercise is believed to enhance muscle IL-15 secretion [75, 76]. In 
fact, secreted IL-15 plays a role as an inflammatory mediator and immune cell chemoattractant 
and has been reported to be involved in the proliferation, differentiation and activation of NK 
cells and CD8+ T cells [77, 78].  Previous work shows IL-15’s role extending in promoting a 
more pro-oxidative phenotype, stimulating heightened fatigue resistance and increasing 
mitochondrial density [4, 39]. This mechanism is the reason for using an IL-15TG - 
overexpressing IL-15 mouse model in our current project. It was hypothesized that this 
additional muscle secreted IL-15 will help attenuate muscle dysfunction that will be seen in this 
cancer-induced model of muscle dysfunction. We saw no significant differences in muscle 
function between any of the groups or conditions (Figures 10-13). Therefore, we are 
inconclusive whether overexpressing IL-15 would potentially rescue muscle function in this 
model. However, there is evidence suggesting that our exposure time of the cancer cell 
conditioned media is insufficient for inducing a change in the contractile function of the EDLs. 
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This may potentially be the reason why the effect of IL-15 is not clearly exhibited.  
   Recent studies conducted by Jackman et al. [9] investigated the effect of cancer cell-
secreted factors by using mouse colon carcinoma cells (C26) on C2C12 skeletal muscle (SKM) 
cells. They measured their conditioned media exposed to the SKM cells at different time points 
for a marker, Leukemia Inhibitory Factor (LIF), which has been identified as the secreted peptide 
that induces myotube atrophy in a C26 mouse model [31]. The researchers found undetectable 
LIF concentrations at the 0 hour and 1 hour time points, but did report an increase of LIF at 2 
hours after incubation, which increased linearly with time [9]. Similarly, McLean et al. [14] 
tested Lewis lung carcinoma conditioned medium (LCM) on C2C12 myotubes at different time 
points to study the effect of LCM cell-secreted factors on mitochondrial electron transport chain 
function and ROS factor production. They found significance in their proteins of interest at the 2 
hour and 24 hour time points, but failed to see an effect at the control and 30 minute time point 
[14]. This evidence suggests that our basic protocol to study the effects of the MDA-MB-231 cell 
line secreted factors on muscle function is unfitting as we may not be allowing enough time for 
the secreted factors to produce an effect on the muscle cells. Nonetheless, it does provide 
evidence for the continuation of developing and enhancing protocols that might be fitting for this 
model. 
  In fact, to test if extended exposure plays a role in our model, we decided to test the last 
two mice left in both of our TG and TG control colonies, under a modified protocol. Each of the 
4 mice were assigned to the 4 different groups (CM TG, UCM TG, CM CON, and UCM CON) 
and were functionally tested with an additional 2 hour pre-incubation in the respective media. 
Since no statistical analyses could be performed, due to only having one sample in each group, 
we decided to plot a graphical representation between the mean of the respective groups with the 
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muscle function of the individual samples with extended exposure (Figures 16 and 17). We 
observe a shift in the EDL fatigue curve to the bottom left in all 4 samples relative to their 
groups. Similar decrease in Area Under the Fatigue Curve were observed, coinciding with the 
graphs, for all of the samples, thereby showing a lower total aggregate force. This demonstrates 
that extended exposure may in fact have a significant effect in our model, both functionally and 
molecularly. Future studies are needed to build on these data and we will also need to modify the 
protocol to use extended exposure across all groups and samples.  
  Another key component of this research that adds novelty to this model is to provide an 
apt physiological model that studies the muscle as a functional unit instead of using cell culture 
models. As to our knowledge, all experiments have so far used cell culture models to study 
pathways and relating them to muscle function. The results represented in Figures 16 and Figure 
17 can be used as a testament to this novelty as we see a similar shape of the fatigue curve across 
all samples, including extended exposure. With this model, we also hope to study the effect of 
cancer cell-secreted factors on molecular pathways and oxidative stress inducing conditions. 
Since elevated levels of ROS are seen in mostly all of the different types of cancers and have 
shown to promote pro-tumorigenic signaling, cancer cell proliferation, and tumor development 
and progression [64], we decided to conduct experiments assessing the protein carbonyl content 
using the OxiSelect Protein Carbonyl Fluorometric Assay. We found no evidence of ROS induced 
carbonylation (Figure 14) and concluded that acute conditioned media exposure does not induce 
oxidative stress. With regards to measuring ROS induced carbonylation using IL-15TG, 
overexpressing IL-15 mice it is important to note that IL-15 has been previously investigated as a 
potential protective mechanism against ROS activity. Li et al. [66] found that pre-incubation with 
IL-15 reduced the activities of intracellular creatine kinase and lactate dehydrogenase, enzymes 
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involved in various metabolic pathways in C2C12 myoblasts exposed to H2O2 mediated oxidative 
stress. We can build on the work done by Li et al. [66] using our model as we can potentially test 
ROS activity by exposing the muscle as a functional unit to H2O2 mediated oxidative stress.  
  Muscle fatigue development has also been attributed to the excess buildup of protons 
(H+) in the muscle cells in response to stimulation [74]. A proton buildup in the cell due to the 
increased glycolytic flux leads to calcium mishandling and aberrant cross-bridge cycling, further 
causing reduced muscle force and muscle fatigue [70, 79]. We decided to measure the pH of the 
media prior to starting the protocol and at the end of the protocol in the WT group. However, we 
saw no significance in the percentage change (Figure 15). In view of the current literature, we 
attributed our findings to possibly having a small sample size. Perhaps the type of stimulation, 
which in this case was a low intensity fatigue protocol could have also been a major contributor 
to our findings. Future work will include pH measurement in all of the groups to have a larger 
sample size and will employ high intensity protocols. 
  Our western blot analyses comparing the level of phosphorylated STAT3 to total STAT3 
had exciting results. Western blot analyses were performed on WT and TG samples exposed to 
the different conditions (CM stimulated, CM unstimulated, UCM stimulated, and UCM 
unstimulated). Figure 18 represents the combined western blot analysis for all of the samples in 
the WT group. No statistical significance was seen in any of the groups. However, we saw an 
opposing result in the western blot analyses of the TG group samples, represented in Figure 19.  
A statistical significant difference (p<0.05) was observed in the phosphorylated STAT3 to total 
STAT3 in the stimulated CM in comparison to the stimulated UCM condition. These data 
suggest that samples that undergo stimulation and are exposed to CM are showing a higher 
significance of phosphorylation of STAT3 that corresponds to increased activation of STAT3. 
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While an increased phosphorylation of STAT3 due to exposure to CM is supported by the 
literature, we observed an increased phosphorylation of STAT3 only in the TG group and not in 
the WT group.  This is crucial since it validates the overexpressing properties of the IL-15TG 
mouse, since IL-15 binding is known to induce and activate the JAK3/STAT3 pathway, 
specifically induce phosphorylation of STAT3.  
  Overall, this research work presented with limitations that need to be addressed to 
improve the model for future work. As discussed, acute exposure may be unfitting for the 
purpose of this project. It is fair to assume that muscle dysfunction will correlate with molecular 
signaling after extended exposure to conditioned media containing cancer cell-secreted factors. 
Another limitation seen in this project is our control media. Despite plating the UCM in identical 
conditions as the CM (same amount of DMEM, incubation time, temperature and localization in 
the same incubator) we believe that media used to grow a non-cancer cell line will serve as a 
better control since the cells would deplete glucose and other nutrients in the DMEM, thus 
minimizing any confounding bias.  
  Although we did not show any differences in the EDLs exposed to the different media 
types or stimulation conditions, we did establish a working model that could be used to further 
the understanding of mechanisms in cancer cachexia. We believe that this model is a novel way 
to test the effects of cancer cell-secreted factors and secretions on muscle function as a whole 
functioning unit. The use of different mice models including the IL-15TG, overexpressor of IL-
15, is useful to evaluate the multidimensional role of cytokine and in this case, the role of IL-15. 
While the immediate need is to establish significant data using the modified protocol with 
extended exposure, this model has translational potential as it simulates an in-vivo environment 
analogous to tumor-bearing animals. With that in mind, using conditioned media from various 
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cancer cell lines can be investigated on multiple signaling pathways that have abnormal 
activation in different diseases states. In conclusion, the research provides support for the sound 
methodology of this ex-vivo model developed for muscle exposure to tumor cell conditioned 
media. 
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CHAPTER 7. 
Supplementary Data 
 
 
 
Supplementary Figure 1: EDL Fatigue curve for all groups. 
Figure S1 shows the EDL fatigue curves for all the conditions (UCM WT, CM WT, UCM TG,CM 
TG, UCM CON, and CM CON). No statistical differences were seen between any of the groups. 
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Supplementary Figure 2: EDL Area Under the Fatigue Curve for all groups. 
Figure S2 shows the EDL Total Area Under the Fatigue Curves (mN*S) for all the conditions 
(UCM WT, CM WT, UCM TG, CM TG, UCM CON, and CM CON). No statistical differences 
were seen between any of the groups. 
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Supplementary Figure 3: Carbonyl Concentration (nmol/mg) in all groups. 
Figure S3 shows the Carbonyl concentrations present in the different groups and conditions 
(UCM & CM WT stimulated, UCM & CM WT unstimulated, UCM & CM TG stimulated, UCM 
& CM TG unstimulated, UCM & CM CON stimulated, UCM & CM CON unstimulated). No 
statistical differences were seen between any of the groups. 
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Supplementary Figure 4: Quantification of pSTAT3 and STAT3 in gel 1 (n= 8) for the WT 
samples.  
Panel A shows the western blot corresponding to gel 1 of the WT samples. Panel B shows the 
quantification of phosphorylated STAT3 to total STAT3. No statistical differences were seen 
between any of the groups. 
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Supplementary Figure 5: Quantification of pSTAT3 and STAT3 in gel 2 (n= 8) for the WT 
samples.  
Panel A shows the western blot corresponding to gel 2 of the WT samples. Panel B shows the 
quantification of phosphorylated STAT3 to total STAT3. No statistical differences were seen 
between any of the groups. 
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Supplementary Figure 6: Quantification of pSTAT3 and STAT3 in gel 1 (n= 8) for the TG 
samples.  
Panel A shows the western blot corresponding to gel 1 of the TG samples. Panel B shows the 
quantification of phosphorylated STAT3 to total STAT3. No statistical differences were seen 
between any of the groups. 
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Supplementary Figure 7: Quantification of pSTAT3 and STAT3 in gel 2 (n= 8) for the TG 
samples.  
Panel A shows the western blot corresponding to gel 2 of the TG samples. Panel B shows the 
quantification of phosphorylated STAT3 to total STAT3. No statistical differences were seen 
between any of the groups. 
 
 
 
 
 
 
	  
	  
